Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on discovering, developing, and commercializing innovative botanical drugs for inflammatory and immune diseases, leveraging a proprietary platform for phytomedicine R&D.

• Lead candidate, Phyto-N, targets multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout, with all programs in preclinical stages.

• Business model anticipates revenue from product sales, licensing, and strategic collaborations post-approval, with initial focus on IND submission for ulcerative colitis in 2026.

• Acquired key IP and preclinical data from related party Duraviva Pharma, consolidating R&D assets and expertise.

Financial performance and metrics

• No revenue generated in 2023, 2024, or Q1 2025; net losses of $361,506 in 2024 and $137,583 in Q1 2025, reflecting early-stage development and IPO preparation costs.

• Cash and equivalents of $198,943 as of March 31, 2025, bolstered by shareholder loans; going concern disclosure included due to recurring losses and reliance on external funding.

• Total shareholders' equity of $365,777 as of March 31, 2025, after asset acquisition and reverse stock split.

Use of proceeds and capital allocation

• Net proceeds of ~$12.1M (at $4.00/share) to fund GLP toxicology and pharmacokinetic studies, clinical trial material manufacturing, Phase I and II trials for Phyto-N in ulcerative colitis, and working capital.

• Full business plan through FDA approval and launch estimated to require over $150M, with future phases dependent on additional financing.